|By Marketwired .||
|June 19, 2014 02:00 AM EDT||
WINNERSH, UNITED KINGDOM -- (Marketwired) -- 06/19/14 -- Vernalis PLC (LSE: VER) (PINKSHEETS: VNLPY)
19 June 2014
Vernalis and Servier achieve Research Milestone
as BCL-2 inhibitor drug candidate enters Phase I
Vernalis plc and Servier today announce the achievement of a milestone following the treatment of the first patient in a Servier sponsored Phase I trial with a promising new drug candidate, a selective BCL-2 inhibitor identified through their joint oncology drug discovery
As a result, Vernalis will receive a payment of EUR1.0 million in recognition of this achievement.
This BCL-2 selective inhibitor is the first drug candidate stemming from an on-going collaboration between Vernalis and Servier aimed at discovering anticancer drug candidates selective for individual BCL-2
Ian Garland, CEO of Vernalis commented: "We are delighted that this new BCL-2 inhibitor candidate has now entered Phase I trials and look forward to further success from our broad, strategic collaboration with Servier."
Jean-Pierre Abastado, Director of the Center of Therapeutic Innovation in Oncology at Servier, said: "Our experience with Vernalis shows that small molecules tailored against specific targets can have very high therapeutic potential. This success was achieved through a comprehensive chemistry and biology research program with our teams identifying and characterizing this promising BCL-2 inhibitor. This new compound further extends Servier's portfolio beyond kinase inhibitors, HDAC inhibitors and immunotherapeutic products."
-- ends --
About BCL-2 target:
Proteins of the BCL-2 family are crucial regulators of apoptosis. Deregulations of this protein family play a major role in the aberrant survival of tumour cells. Within this protein family, BCL-2 belongs to the pro-survival members and is often overexpressed in tumour cells. Pro-survival BCL-2 family members have been recognized as attractive therapeutic targets in oncology for more than twenty years but drug discovery research on this class of target is particularly challenging and requires innovative chemistry supported by structural biology.
Founded in 1954, Servier is an independent French pharmaceutical research company. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular-, metabolic-, neurologic-, psychiatric-, bone- and joint diseases as well as cancer. In 2013, the company recorded a turnover of 4.2 billion euros. 91% of Servier drugs are consumed outside France. 27% of turnover from Servier drugs were reinvested in Research and Development in 2013. With a strong international presence in 140 countries, Servier employs more than 21000 people worldwide. The Servier Group contributed 35% to the 2013 French trade surplus in the pharmaceuticals sector.
More information is available at:www.servier.com
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
This information is provided by RNS
The company news service from the London Stock Exchange
Chief Executive Officer
Chief Financial Officer
+44 (0) 118 938 0015
Canaccord Genuity Limited (Nominated Adviser):
Dr Julian Feneley
+44 (0) 20 7523 8350
Shore Capital (Joint Broker):
+44 (0)20 7408 4090
+44 (0) 20 7404 5959
Servier Communication Department
+33 1 5572 6037
If you had a chance to enter on the ground level of the largest e-commerce market in the world – would you? China is the world’s most populated country with the second largest economy and the world’s fastest growing market. It is estimated that by 2018 the Chinese market will be reaching over $30 billion in gaming revenue alone. Admittedly for a foreign company, doing business in China can be challenging. Often changing laws, administrative regulations and the often inscrutable Chinese Interne...
Oct. 26, 2016 06:00 AM EDT Reads: 1,394
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
Oct. 26, 2016 06:00 AM EDT Reads: 1,840
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Oct. 26, 2016 06:00 AM EDT Reads: 2,031
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
Oct. 26, 2016 06:00 AM EDT Reads: 1,535
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Oct. 26, 2016 05:45 AM EDT Reads: 2,549
Oct. 26, 2016 05:30 AM EDT Reads: 1,036
Oct. 26, 2016 05:30 AM EDT Reads: 1,011
Oct. 26, 2016 05:00 AM EDT Reads: 991
Oct. 26, 2016 05:00 AM EDT Reads: 2,567
Oct. 26, 2016 04:45 AM EDT Reads: 944
Oct. 26, 2016 04:30 AM EDT Reads: 1,759
Oct. 26, 2016 04:30 AM EDT Reads: 1,193
Oct. 26, 2016 04:15 AM EDT Reads: 1,163
Oct. 26, 2016 03:45 AM EDT Reads: 1,330
Oct. 26, 2016 03:45 AM EDT Reads: 1,020